Professional
Added to YB: 2024-04-16
Pitch date: 2024-04-10
CORT [bullish]
Corcept Therapeutics Incorporated
+148.6%
current return
Author Info
No bio for this author
Company Info
Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States.
Market Cap
$6.1B
Pitch Price
$24.01
Price Target
N/A
Dividend
N/A
EV/EBITDA
-1.3K
P/E
141.99
EV/Sales
7.31
Sector
Pharmaceuticals
Category
growth
ClearBridge Small Cap Strategy New Portfolio Holding: Corcept Therapeutics Incorporated
CORT: Biotech focused on endocrine, oncology, metabolic & neuro disorders. Korlym, for Cushing's Syndrome, at $482M sales despite new generic threat. Upcoming next-gen drug Ph3 data soon: better safety, more indications = larger market. Rare disease + specialty distribution limit generic risk.
Read full article (1 min)